Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback